Eagle Asset Management Inc. boosted its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 36.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,365,794 shares of the company’s stock after purchasing an additional 367,687 shares during the period. Eagle Asset Management Inc. owned 3.60% of Omnicell worth $66,047,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Marco Investment Management LLC acquired a new stake in shares of Omnicell in the third quarter worth about $231,000. Stevens Capital Management LP acquired a new stake in shares of Omnicell in the third quarter worth about $305,000. 1st Global Advisors Inc. lifted its position in shares of Omnicell by 1.5% in the second quarter. 1st Global Advisors Inc. now owns 7,948 shares of the company’s stock worth $343,000 after buying an additional 120 shares during the last quarter. Piedmont Investment Advisors LLC acquired a new stake in shares of Omnicell in the second quarter worth about $346,000. Finally, Sei Investments Co. lifted its position in shares of Omnicell by 76.7% in the third quarter. Sei Investments Co. now owns 8,219 shares of the company’s stock worth $420,000 after buying an additional 3,567 shares during the last quarter. 99.87% of the stock is owned by hedge funds and other institutional investors.
In related news, CFO Peter J. Kuipers sold 1,926 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $51.69, for a total transaction of $99,554.94. Following the completion of the transaction, the chief financial officer now owns 40,544 shares of the company’s stock, valued at approximately $2,095,719.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.77% of the stock is currently owned by insiders.
Omnicell, Inc. (NASDAQ:OMCL) opened at $44.25 on Friday. Omnicell, Inc. has a 12-month low of $35.00 and a 12-month high of $55.40. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.28 and a current ratio of 1.73. The firm has a market capitalization of $1,631.09, a PE ratio of 252.94, a P/E/G ratio of 3.55 and a beta of 0.65.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.02. Omnicell had a return on equity of 1.54% and a net margin of 2.88%. The business had revenue of $198.26 million during the quarter, compared to analysts’ expectations of $205.50 million. During the same quarter in the previous year, the firm earned $0.37 EPS. The firm’s revenue was up 13.6% compared to the same quarter last year. analysts forecast that Omnicell, Inc. will post 0.77 earnings per share for the current fiscal year.
OMCL has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $63.00 price target on shares of Omnicell in a research report on Thursday, February 1st. Oppenheimer reaffirmed a “buy” rating and issued a $55.00 price target on shares of Omnicell in a research report on Monday, January 29th. Craig Hallum reaffirmed a “buy” rating and issued a $62.00 price target (up previously from $52.00) on shares of Omnicell in a research report on Monday, October 30th. Zacks Investment Research raised Omnicell from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Finally, Piper Jaffray Companies boosted their price target on Omnicell from $38.00 to $44.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Omnicell currently has an average rating of “Hold” and a consensus price target of $56.14.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.